Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

× No keyword cloud information.

27 in total

Review 1. Current treatment options for pancreatic carcinoma.

Authors: Emily Castellanos; Jordan Berlin; Dana Backlund Cardin
Journal: Curr Oncol Rep Date: 2011-06 Impact factor: 5.075

Review 2. End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy.

Authors: Biren Saraiya; Susan Bodnar-Deren; Elaine Leventhal; Howard Leventhal
Journal: Cancer Date: 2008-12-15 Impact factor: 6.860

3. Risk in clinical research: size matters!

Authors: Pedro R Lowenstein
Journal: Mol Ther Date: 2009-11 Impact factor: 11.454

4. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.

Authors: Yuriko Sasahara; Hiroto Narimatsu; Akira Fukao; Takashi Yoshioka
Journal: Int J Clin Oncol Date: 2016-04-22 Impact factor: 3.402

Review 5. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?

Authors: Namrata Vijayvergia; Steven J Cohen
Journal: J Gastrointest Oncol Date: 2016-10

Review 6. Advanced-stage pancreatic cancer: therapy options.

Authors: Jens Werner; Stephanie E Combs; Christoph Springfeld; Werner Hartwig; Thilo Hackert; Markus W Büchler
Journal: Nat Rev Clin Oncol Date: 2013-04-30 Impact factor: 66.675

7. Comparative effectiveness and health care spending--implications for reform.

Authors: Milton C Weinstein; Jonathan A Skinner
Journal: N Engl J Med Date: 2010-01-06 Impact factor: 91.245

8. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.

Authors: Elena Galvani; Elisa Giovannetti; Francesca Saccani; Andrea Cavazzoni; Leticia G Leon; Henk Dekker; Roberta Alfieri; Caterina Carmi; Marco Mor; Andrea Ardizzoni; Pier Giorgio Petronini; Godefridus J Peters
Journal: Neoplasia Date: 2013-01 Impact factor: 5.715

Review 9. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Authors: Pedro R Lowenstein; Maria G Castro
Journal: Curr Gene Ther Date: 2009-10 Impact factor: 4.391

10. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Authors: Bryan A Faller; Barbara Burtness
Journal: Biologics Date: 2009-09-15